和黃醫藥啟動HMPL-453治療晚期惡性間皮瘤患者II期臨床試驗
和黃醫藥公布,啟動了一項HMPL-453治療晚期惡性間皮瘤患者的II期臨床試驗。 HMPL-453是一種靶向成纖維細胞生長因子受體的新型小分子抑製劑。
該研究是一項單臂、多中心、開放標籤的臨床試驗,旨在評估HMPL-453在至少經過一線全身性治療失敗後的晚期惡性間皮瘤患者中的療效、安全性和藥代動力學特性。
研究的主要結果指標為客觀緩解率(ORR)。次要結果指標包括初步療效,例如疾病控制率(DCR)、到達疾病緩解的時間(TTR)、緩解持續時間(DoR)、無進展生存期(PFS)和總生存期(OS)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.